217P Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced unacceptable toxicity
C. Benvenuti, Rita De Sanctis(Humanitas University), M. Mokdad(Institut Gustave Roussy), Alberto Zambelli, A.A. Viansone(Institut Gustave Roussy), Mariangela Gaudio(Humanitas University), Riccardo Gerosa(Humanitas University), J.Z. Zeghondy(Institut Gustave Roussy), Flavia Jacobs(Fondazione IRCCS Istituto Nazionale dei Tumori), Giuseppe Saltalamacchia, C. Poisson(Institut Gustave Roussy), Jacopo Canzian(Humanitas University), L. Clapis(Humanitas University), B. Pistilli(Institut Gustave Roussy), Armando Santoro(IRCCS Humanitas Research Hospital), Thomas Grinda(Institut Gustave Roussy)
Cited by 2
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532